ArticlePediatric research2026
Attenuation of Experimental Bronchopulmonary Dysplasia by Dimethyl Fumarate.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bronchopulmonary dysplasia and prematurity-associated lung disease: emerging therapies to improve lifelong respiratory outcomes.European journal of pediatrics · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInnovative therapies for bronchopulmonary dysplasia (BPD) in neonates are needed. Dimethyl fumarate (DMF) is a methyl ester of fumaric acid that is an approved drug. The goal was to explore the role of DMF in BPD utilizing a hyperoxia-induced murine model of experimental BPD.
methodsIn our mouse model of experimental moderate-BPD, DMF was administered on postnatal (PN) days 2 and 4. On PN14, we evaluated lung histology, lung morphometry, and used Western blotting.
resultsDMF improved lung histology in male and female mice, with recovery of chord length, septal thickness, and radial alveolar counts. There was a significant reduction in cell death, increase in cell proliferation, and lung vascularization after DMF treatment. Nuclear factor erythroid -2-related factor (Nrf-2) expression decreased, while nuclear factor-kappa-light-chain enhancer of activated B cells (NF-κB) expression levels increased in the BPD lungs. These effects were reversed after treatment with DMF. We found a decrease in heme oxygenase (HO)-1 expression after DMF treatment, with no change in selective mitochondrial markers of oxidative stress.
conclusionThis is the first study to demonstrate the efficacy of systemically administered DMF to promote the resolution of experimental moderate-BPD. DMF putatively acted via Nrf-2 -dependent and -independent cell signaling pathways. IMPACT: 1. Dimethyl fumarate (DMF) is an approved drug for lung fibrosis treatment. 2. We used our experimental moderate-BPD mouse model to evaluate the impact of DMF treatment. 3. DMF improved lung histology and morphometry, with a significant reduction in cell death, and an increase in cell proliferation and lung vascularization after DMF treatment. 4. Nrf-2 expression decreased in response to hyperoxia in male and female lungs, while NF-κB expression levels increased. These were reversed with DMF treatment. 5. This is the first study to demonstrate the efficacy of DMF to promote the resolution of experimental moderate-BPD in the mouse model.
Identifiers
42143183What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.